Prestige Consumer Healthcare Inc PBH

Morningstar Rating
$48.22 +0.22 (0.46%)
View Full Chart

Company Report

Price vs Fair Value

PBH is trading at a LOCK|@QXQtF premium.
Price
$48.00
Fair Value
$hv
Uncertainty
LOCK|P#%L
1-Star Price
LOCK|.g
5-Star Price
f#H
Economic Moat
LOCK|>>z$#
Capital Allocation
LOCK|QP!vxy

Bulls Say, Bears Say

Bulls

Prestige is well positioned to enjoy macro long-term trends, including aging population, rising awareness of self-care, and premiumization of consumer healthcare.

Bears

Emerging large players in the consumer healthcare space, including Haleon and Kenvue, have the resources to expand their portfolios and displace smaller brands that Prestige owns.

News

Articles & Videos

Trading Information

Previous Close Price
$48.00
Day Range
$47.43–48.79
52-Week Range
$41.77–71.07
Bid/Ask
$41.57 / $53.08
Shares Outstanding
47.40M
Market Cap
$2.29B
Volume/Avg
597,838 / 571,950

Key Statistics

Price/Earnings (Normalized)
10.86
Price/Sales
1.96
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
2.04%

Company Profile

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
890

Competitors

Valuation

Metric
PBH
PG
HLN
Price/Earnings (Normalized)
10.8625.0819.16
Price/Book Value
1.177.301.87
Price/Sales
1.964.752.75
Price/Cash Flow
8.8921.5614.20
Price/Earnings
PBH
PG
HLN

Financial Strength

Metric
PBH
PG
HLN
Quick Ratio
1.720.490.51
Current Ratio
2.920.720.69
Interest Coverage
4.2223.117.45
Quick Ratio
PBH
PG
HLN

Profitability

Metric
PBH
PG
HLN
Return on Assets (Normalized)
5.42%12.95%5.49%
Return on Equity (Normalized)
11.36%30.92%10.94%
Return on Invested Capital (Normalized)
7.81%18.72%8.05%
Return on Assets
PBH
PG
HLN

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|!&jlV<hRLOCK|&vl&$72B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|FBC^X<!LOCK|YNnh$51B
Haleon PLC ADR
HLN
LOCK|xV?M$xQLOCK|?J$40B
Zoetis Inc Class A
ZTS
LOCK|L@gwksBBLOCK|bW$34B
Viatris Inc
VTRS
LOCK|d$X!XtLOCK|@MZ$24B
Elanco Animal Health Inc
ELAN
LOCK|cdLOCK|x#$13B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|jT$W@SLOCK|!T$12B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|WSt!kt$LOCK|YK$4B
Perrigo Co PLC
PRGO
LOCK|yRc%pBLOCK|!@?$2B

Sponsor Center